(Q44103626)

29 November 2017

title

A prognostic score for patients with lower risk myelodysplastic syndrome (English)

1 reference

29 November 2017

Garcia-Manero G

1

1 reference

29 November 2017

Shan J

2

1 reference

29 November 2017

Faderl S

3

1 reference

29 November 2017

Cortes J

4

1 reference

29 November 2017

Ravandi F

5

1 reference

29 November 2017

Borthakur G

6

1 reference

29 November 2017

Wierda WG

7

1 reference

29 November 2017

Pierce S

8

1 reference

29 November 2017

Estey E

9

1 reference

29 November 2017

Liu J

10

1 reference

29 November 2017

Huang X

11

1 reference

29 November 2017

Kantarjian H

12

1 reference

29 November 2017

publication date

13 December 2007

1 reference

29 November 2017

1 reference

29 November 2017

volume

22

1 reference

29 November 2017

issue

3

1 reference

29 November 2017

page(s)

538-543

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2405070

29 November 2017

exact match

0 references

cites work

Proposals for the classification of the myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405070

The World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405070

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405070

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405070

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405070

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405070

Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405070

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405070

Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405070

Contribution of β-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405070

21 January 2018

Identifiers

DOI

10.1038/SJ.LEU.2405070

1 reference

29 November 2017

1 reference